parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	genetic association 0.07 (overall 0.04)	0.07
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in distal convoluted tubule cells	0.75
chemistry Open Targets	hard to drug	0.27
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	5 Parkinson's papers of 18	0.76
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 5725

ARL17A in microglia, braak+0.30 (p 0.428) → -0.05 (p 0.891)receipt 5731
ARL17A in dopamine neurons, braak-0.66 (p 0.053) → -0.06 (p 0.877)receipt 5732

receipt 5732: ARL17A in dopamine neurons, braak

power: full sample -0.40 (p 0.101, n 18), 95% CI -0.73 to +0.08. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.39 (p 0.111, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.127, n 18). could be the mix.
skeptic: leave-one-out range -0.52 to -0.33, sign flips 0; without severely affected donors -0.40 (p 0.101, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ARL17A in dopamine neurons.

case closed: nothing better to follow up.

receipt 5731: ARL17A in microglia, braak

power: full sample +0.08 (p 0.767, n 18), 95% CI -0.41 to +0.52. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.05 (p 0.834, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.16 (p 0.515, n 18). could be the mix.
skeptic: leave-one-out range -0.04 to +0.21, sign flips 2; without severely affected donors +0.08 (p 0.767, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for ARL17A in microglia.

case closed: nothing better to follow up.

loading the receipts